Mayne Pharma Group to Respond to US FDA Letter Within Prescribed Timeframe

MT Newswires Live

2025/05/14

Mayne Pharma Group (ASX:MYX) said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.

It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.

It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.

Its shares fell 13% on market close on Wednesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535992096"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535992096\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535992096?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 14:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535992096","market":"sg","top_or_hot":-1,"title":"Mayne Pharma Group to Respond to US FDA Letter Within Prescribed Timeframe","media":"MT Newswires Live","content":"<html><body><p> Mayne Pharma Group (ASX:MYX) said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.</p><p>It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.</p><p>It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.</p><p>Its shares fell 13% on market close on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mayne Pharma Group to Respond to US FDA Letter Within Prescribed Timeframe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMayne Pharma Group to Respond to US FDA Letter Within Prescribed Timeframe\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-14 14:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mayne Pharma Group (ASX:MYX) said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.</p><p>It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.</p><p>It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.</p><p>Its shares fell 13% on market close on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2535992096","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535992096","pubTimestamp":1747204293,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mayne Pharma Group  said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.Its shares fell 13% on market close on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","MYX.AU":"MAYNE PHARMA GROUP LTD","BK7096":"制药"},"translate_title":"梅恩制药集团将在规定时间内回复美国FDA信函","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYX.AU":0.9},"content_text":"Mayne Pharma Group (ASX:MYX) said it takes the views of the US Food and Drug Administration seriously and it will respond to an untitled letter sent by the regulator within the prescribed timeframe, according to a Wednesday Australian bourse filing.It received an untitled letter from the US FDA Office of Prescription Drug Promotion on April 28, related to certain promotional claims used in a speaker presentation for NEXTSTELLIS, a combined oral contraceptive.It said it voluntarily withdrew the speaker presentation referenced in the letter. The matter is not expected to impact the firm's ability to continue to sell and distribute NEXTSTELLIS in the US.Its shares fell 13% on market close on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}